SMART-SF Radiofrequency Ablation Safety Study

Inclusion Criteria: * Symptomatic paroxysmal atrial fibrillation (AF) who have had at least one AF episode electrocardiographically documented within one (1) year prior to enrollment and a physician's note indicating recurrent, self-terminating AF. Electrocardiographic documentation may include, but is not limited to, electrocardiogram (ECG), transtelephonic monitor (TTM), Holter monitor (HM), or telemetry strip * Failed at least one antiarrhythmic drug (AAD) (class I or III, or atrioventricular (AV) nodal blocking agents such as beta blockers and calcium channel blockers) as evidenced by recurrent symptomatic AF, or intolerable to the AAD * Age 18 years or older Exclusion Criteria: * Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause * Previous surgical or catheter ablation for atrial fibrillation * Amiodarone at any time during the past 3 months * Any percutaneous coronary intervention (PCI), cardiac surgery, or valvular cardiac surgical or percutaneous procedure (e.g., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve) within the past 2 months * Any carotid stenting or endarterectomy * Coronary artery bypass graft (CABG) surgery within the past 6 months * AF episodes lasting \>7 days * Documented left atrial (LA) thrombus on imaging * LA size \>50 mm * Left ventricular ejection fraction (LVEF) \< 40% * Contraindication to anticoagulation (heparin or warfarin) * History of blood clotting or bleeding abnormalities * MI within the past 2 months * Documented thromboembolic event (including transient ischemic attack (TIA)) within the past 12 months * Rheumatic Heart Disease * Uncontrolled heart failure or New York Heart Association (NYHA) function class III or IV * Awaiting cardiac transplantation or other cardiac surgery within the next 12 months * Unstable angina * Acute illness or active systemic infection or sepsis * Diagnosed atrial myxoma * Presence of implanted implantable cardioverter defibrillator (ICD) * Significant pulmonary disease, (eg, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms * Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study * Women who are pregnant (as evidenced by pregnancy test if pre-menopausal) * Enrollment in an investigational study evaluating another device, biologic, or drug * Presence of intramural thrombus, tumor or other abnormality that precludes vascular access, or manipulation of the catheter * Presence of a condition that precludes vascular access * Life expectancy or other disease processes likely to limit survival to less than 6 months